| Company/Division name | CytoImmune Therapeutics Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 28 |
| Country(ies) from which reshored: | United States |
| City reshored to: | Toa Baja |
| State(s) reshored to: | PR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biologics, novel cancer immunotherapy products |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Skilled workforce availability/training |
